San Francisco, 10 December 2018: Global circulating tumor cells market is anticipated to reach USD 11,552.3
million by 2022, according to a new report by Grand View Research, Inc. Rising
developments in the field of biomedical engineering and biomedical imaging
coupled with rise in patented research initiatives by the government is
expected to drive this industry through the forecast period.
Introduction of novel technologies for
enumeration of circulating tumor cells is anticipated to fuel growth in this
sector through to 2022. Furthermore, increasing incidences of chronic oncology
diseases that depend on the detection and analysis of CTCs, as it has enormous
potential in the real-time monitoring of cancer therapy, over the
conventional methods such as imaging technologies and tumor tissue
biopsy.
Additionally, application of CTC as
biomarkers for drug discovery is a promising factor for growth in the coming
years. Utilization of the circulating tumor cells in development of tumor
specific biomarkers in order to optimize the selection of targeted therapies
and assessment of better response to the therapy is expected to support in the
projected growth of CTC market in the coming years.
Access
Research Report of Circulating Tumor Cells
Market @ www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
Further key findings from the study suggest:
· CTC enrichment accounted for the largest
share of market revenue in 2014 and is expected to continue this dominance
owing to high usage rates in oncology research establishments and high accuracy
exhibited by this technology.
· Microchips technology is anticipated to
register substantial growth in the next seven years because of the introduction
of cluster chip technology that enables capture of clusters of tumor cells for
CTC quantitation.
· Characteristic property of the cancer stem
cells of self-renewal in replenishing the growing cancer is driving the
attention of organizations and researchers in CTC cancer stem cell research
segment thus accounting for the segment’s large share in revenue generation.
· Application of alterations witnessed in the
expression profiles of EMT-associated transcriptional regulators and their
molecular targets as biomarkers in EMT study is expected to serve as an impetus
for diagnosis of tumour recurrence consequently driving the segment with a
double digit CAGR of over 10%.
· North America dominated the market in 2014,
with revenue estimation that accounted for over 45% of the global market.
Presence of strong oncology research funding, refined healthcare
infrastructure, growing incidence of cancer, favorable government initiatives
with respect to R&D funding for clinical diagnostic products are factors
attributive for larger revenue share.
· Asia Pacific is anticipated to witness
lucrative CAGR of over 16% as a result of infrastructure development in care
centers coupled with increase in sales of CTC diagnostic tests. The need of new
diagnosis methods for the growing cancer cases has gushed up research on new
developments in developing economies of this region thus providing potential
avenues for market growth.
· Key participants of CTC industry include
Canopus Biosciences, Clearbridge BioMedics, Fluxion Biosciences, Janssen
Diagnostics, Adnagen, Advanced Cell Diagnostics, Apocell, Vitatex Inc.,
Miltenyi Biotech Cynvenio Biosystems, Aviva Biosciences, Biocept Inc.,
Biofluidica, Creatv Microtech Inc., Ikonisys Inc., Epic Biosciences, Biocep
Ltd., Greiner Bio-one GmbH, Sysmex Corporation, and CellTraffix Inc.
· These market entities are involved in
collaborations with hospitals and university based research institutes in order
to gain access to target population and develop novel technologies for CTC
enrichment & detection.
Browse more reports of this category by Grand View
Research at: www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented
circulating tumor cells market on the basis of technology, application, and
region:
Global Circulating Tumor Cell
Technology Outlook (Revenue, USD Million, 2012 - 2022)
·
CTC Enrichment
·
CTC Detection
·
CTC Analysis
Global Circulating Tumor Cell Application
Outlook (Revenue, USD Million, 2012 - 2022)
·
Tumorigenesis research
·
EMT biomarkers development
·
Cancer stem cell research
·
Others
Circulating Tumor Cell Regional Outlook
(Revenue, USD Million, 2012 - 2022)
·
North America
·
Europe
·
Asia Pacific
·
Latin America
·
MEA
Access Press Release of
Circulating Tumor Cells Market@ www.grandviewresearch.com/press-release/global-circulating-tumor-cells-market
About
Grand View Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco.
The company provides syndicated research reports, customized research
reports, and consulting services. To help clients make informed business
decisions, we offer market intelligence studies ensuring relevant and
fact-based research across a range of industries, from technology to chemicals,
materials and healthcare.
No comments:
Post a Comment